Merck’s KEYTRUDA (pembrolizumab) Receives CHMP Recommendation for 1L Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

 Merck’s KEYTRUDA (pembrolizumab) Receives CHMP Recommendation for 1L Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Merck’s KEYTRUDA (pembrolizumab) Receives CHMP Recommendation for 1L Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Shots:

  • The positive opinion is based on P-III KEYNOTE-407 trials results assessing Keytruda + CT (carboplatin/paclitaxel/nab-paclitaxel) vs CT monothx. in patients with msq NSCLC
  • The P-III KEYNOTE-407 trials resulted in improved OS & PFS and demonstrated rates of alopecia (47% vs 36%) and peripheral neuropathy (31% vs 25%), were presented at ASCO 2018
  • Keytruda (pembrolizumab) 100mg IV is a mAb, used as an anti-D-L1 therapy that blocks the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2, further activating T lymphocytes. The CHMP opinion will be reviewed by EU for its futher approval, expected in H1’19

Click hereto read full press release/ article | Ref: Merck | Image: IndustryWeek

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post